{"id":"https://openalex.org/W2419630271","doi":"https://doi.org/10.1007/978-1-59745-554-1_28","title":"Neutralization of HIV by Antibodies","display_name":"Neutralization of HIV by Antibodies","publication_year":2008,"publication_date":"2008-12-10","ids":{"openalex":"https://openalex.org/W2419630271","doi":"https://doi.org/10.1007/978-1-59745-554-1_28","mag":"2419630271","pmid":"https://pubmed.ncbi.nlm.nih.gov/19252841"},"language":"en","primary_location":{"id":"doi:10.1007/978-1-59745-554-1_28","doi":"https://doi.org/10.1007/978-1-59745-554-1_28","is_oa":false,"landing_page_url":"https://doi.org/10.1007/978-1-59745-554-1_28","pdf_url":null,"source":{"id":"https://openalex.org/S4210172139","display_name":"Methods in molecular biology","issn_l":"1064-3745","issn":["1064-3745","1940-6029"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"book series"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Methods in Molecular Biology\u2122","raw_type":"book-chapter"},"volume":{"id":"https://openalex.org/W2417715858","display_name":"Therapeutic Antibodies"},"type":"book-chapter","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066788024","display_name":"Ilia Prado","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127751","display_name":"Profectus Biosciences (United States)","ror":"https://ror.org/02zy72z44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127751"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ilia Prado","raw_affiliation_strings":["Profectus BioSciences, Inc., Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Profectus BioSciences, Inc., Baltimore, MD, USA","institution_ids":["https://openalex.org/I4210127751"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031256695","display_name":"TIMOTHY R. FOUTS","orcid":"https://orcid.org/0000-0002-2429-2859","observed_orcids":["https://orcid.org/0000-0002-2429-2859"]},"institutions":[{"id":"https://openalex.org/I4210127751","display_name":"Profectus Biosciences (United States)","ror":"https://ror.org/02zy72z44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127751"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy R. Fouts","raw_affiliation_strings":["Profectus BioSciences, Inc., Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Profectus BioSciences, Inc., Baltimore, MD, USA","institution_ids":["https://openalex.org/I4210127751"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091829422","display_name":"Antony S. Dimitrov","orcid":"https://orcid.org/0000-0001-8356-6701","observed_orcids":["https://orcid.org/0000-0001-8356-6701"]},"institutions":[{"id":"https://openalex.org/I4210127751","display_name":"Profectus Biosciences (United States)","ror":"https://ror.org/02zy72z44","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127751"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Antony S. Dimitrov","raw_affiliation_strings":["Profectus BioSciences, Inc., Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Profectus BioSciences, Inc., Baltimore, MD, USA","institution_ids":["https://openalex.org/I4210127751"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210127751"],"apc_list":null,"apc_paid":null,"fwci":2.6443,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.89411765,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"525","issue":null,"first_page":"517","last_page":"531"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv-1-neutralization","display_name":"HIV-1 neutralization","score":0.9079999923706055},{"id":"https://openalex.org/keywords/neutralizing-antibodies","display_name":"neutralizing antibodies","score":0.8989999890327454},{"id":"https://openalex.org/keywords/antibody-potency","display_name":"antibody potency","score":0.5600000023841858},{"id":"https://openalex.org/keywords/antibody-cross-reactivity","display_name":"antibody cross-reactivity","score":0.6830000281333923},{"id":"https://openalex.org/keywords/antigen-binding-affinity","display_name":"antigen binding affinity","score":0.7860000133514404},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.8939999938011169},{"id":"https://openalex.org/keywords/hiv-entry","display_name":"HIV entry","score":0.41200000047683716},{"id":"https://openalex.org/keywords/immune-evasion","display_name":"immune evasion","score":0.6909999847412109},{"id":"https://openalex.org/keywords/therapeutic-antibodies","display_name":"therapeutic antibodies","score":0.7599999904632568},{"id":"https://openalex.org/keywords/hiv-vaccine-design","display_name":"HIV vaccine design","score":0.6119999885559082}],"concepts":[{"id":"https://openalex.org/C14086860","wikidata":"https://www.wikidata.org/wiki/Q337120","display_name":"Neutralization","level":3,"score":0.8086615800857544},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5823708772659302},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5539775490760803},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.5096426010131836},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3204832971096039},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2749711573123932}],"mesh":[{"descriptor_ui":"D000914","descriptor_name":"Antibodies, Viral","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007135","descriptor_name":"Immunoglobulin Variable Region","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008213","descriptor_name":"Lymphocyte Activation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008214","descriptor_name":"Lymphocytes","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D009500","descriptor_name":"Neutralization Tests","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000302","qualifier_name":"isolation & purification","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D016655","descriptor_name":"HIV Core Protein p24","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D017186","descriptor_name":"Titrimetry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020128","descriptor_name":"Inhibitory Concentration 50","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/978-1-59745-554-1_28","doi":"https://doi.org/10.1007/978-1-59745-554-1_28","is_oa":false,"landing_page_url":"https://doi.org/10.1007/978-1-59745-554-1_28","pdf_url":null,"source":{"id":"https://openalex.org/S4210172139","display_name":"Methods in molecular biology","issn_l":"1064-3745","issn":["1064-3745","1940-6029"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"book series"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Methods in Molecular Biology\u2122","raw_type":"book-chapter"},{"id":"pmid:19252841","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19252841","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Methods in molecular biology (Clifton, N.J.)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9047999978065491,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8199999928474426,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W33974125","https://openalex.org/W56308928","https://openalex.org/W1966140905","https://openalex.org/W1973489387","https://openalex.org/W1976244486","https://openalex.org/W1977509185","https://openalex.org/W1988257424","https://openalex.org/W1995508556","https://openalex.org/W2000986010","https://openalex.org/W2015796602","https://openalex.org/W2021877795","https://openalex.org/W2030633257","https://openalex.org/W2030837678","https://openalex.org/W2031637541","https://openalex.org/W2038114373","https://openalex.org/W2038610417","https://openalex.org/W2042938988","https://openalex.org/W2045039560","https://openalex.org/W2048386706","https://openalex.org/W2051785641","https://openalex.org/W2067464226","https://openalex.org/W2069141624","https://openalex.org/W2071200370","https://openalex.org/W2074734900","https://openalex.org/W2077153526","https://openalex.org/W2087272863","https://openalex.org/W2099697190","https://openalex.org/W2102670802","https://openalex.org/W2110937893","https://openalex.org/W2115679902","https://openalex.org/W2116759309","https://openalex.org/W2125231927","https://openalex.org/W2139266935","https://openalex.org/W2148825772","https://openalex.org/W2155058406","https://openalex.org/W2155449170","https://openalex.org/W2157138119","https://openalex.org/W2167786748","https://openalex.org/W2275351935","https://openalex.org/W2318289184","https://openalex.org/W4242554003","https://openalex.org/W4296391115"],"related_works":["https://openalex.org/W2049967024","https://openalex.org/W7023373330","https://openalex.org/W2021085054","https://openalex.org/W4408947327","https://openalex.org/W2147947123","https://openalex.org/W2326106166","https://openalex.org/W2406447630","https://openalex.org/W2031637541","https://openalex.org/W2049457179","https://openalex.org/W2036540236"],"abstract_inverted_index":{"Antibodies":[0],"can":[1],"neutralize":[2],"HIV-1":[3],"with":[4,146],"potency":[5,164],"and":[6,11,50,58,109,167,170,185],"cross-reactivity":[7],"that":[8],"varies":[9],"widely":[10,95],"is":[12,38,129],"related":[13],"but":[14,132],"not":[15],"correlated":[16],"to":[17,24],"their":[18],"antigen-binding":[19],"affinity.":[20],"Therefore,":[21],"in":[22,35,73,85,100,123,133,142,149,165],"addition":[23],"measuring":[25],"binding":[26],"affinity,":[27],"an":[28,159],"evaluation":[29],"of":[30,42,46,54,60,65,71,77,94,114,140,154,161,179],"the":[31,52,72,78,86,125,141,152,162,177],"antibody":[32,79,163],"neutralizing":[33,75],"activity":[34],"tissue":[36],"cultures":[37],"important":[39],"for":[40,69,176],"development":[41,64,178],"antibody-based":[43],"therapeutics,":[44],"design":[45],"candidate":[47],"vaccine":[48],"immunogens,":[49],"understanding":[51],"mechanisms":[53],"virus":[55],"entry,":[56],"neutralization,":[57],"evasion":[59],"immune":[61],"responses.":[62],"The":[63],"a":[66,82,137],"standardized":[67],"assay":[68],"measurement":[70],"vitro":[74,150],"activities":[76],"has":[80],"remained":[81],"challenging":[83],"goal":[84],"last":[87],"two":[88,92],"decades.":[89],"There":[90],"are":[91,157,174],"types":[93],"used":[96],"assays,":[97],"which":[98,128],"vary":[99],"details":[101],"between":[102],"different":[103],"laboratories--assays":[104],"based":[105,111],"on":[106,112],"cell":[107],"line/pseudovirus":[108],"assays":[110,151],"infection":[113],"peripheral":[115],"blood":[116],"mononuclear":[117],"cells":[118],"(PBMCs).":[119],"Here":[120],"we":[121],"describe":[122],"detail":[124],"PBMC-based":[126],"assay,":[127],"more":[130],"laborious":[131],"our":[134],"opinion":[135],"represents":[136],"closer":[138],"approximation":[139],"vivo":[143],"situation.":[144],"As":[145],"all":[147],"other":[148],"results":[153],"such":[155,180],"measurements":[156],"only":[158],"indication":[160],"vivo,":[166],"animal":[168],"studies":[169],"ultimately":[171],"clinical":[172],"trials":[173],"needed":[175],"antibodies":[181],"as":[182],"potential":[183],"prophylactics":[184],"therapeutics.":[186]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}